🌎 Clinakos is heading to the Intellus’ Worldwide 2026 Summit, the leading forum for healthcare insights, analytics, and evidence generation.

Half of FDA’s 2025 approvals targeted rare diseases. Real-world data made the difference.🧬 In 2025, rare diseases dominated the FDA

📅 2026 FDA PDUFA Calendar Highlights a Pivotal Year for Rare Disease Innovation Beyond headline approvals, the FDA’s 2026 calendar

🔍 Understanding rare disease patients starts with seeing the full story behind every symptom, delay, and misdiagnosis—not just the ICD

Patients, providers, and life sciences partners are all betting on the same thing: that the data connecting them is protected

Join us on February 4, 2026, for an engaging discussion on how AI agents are transforming the way patient-level data

Join Clinakos Inc. at the J.P. Morgan Healthcare Conference 2026, where the future of medicine is shaped by insight, innovation,

In December 2025, the U.S. Food and Drug Administration (FDA) officially deployed Agentic AI capabilities across all agency teams —

Piper Sandler this year was a powerful reminder of how quickly the ground is shifting under our feet for life

One patient. One mutation. One groundbreaking approach to gene editing. 🔬 🚀 Recently, researchers at the Children’s Hospital of Philadelphia